Abstract: A method for treatment and/or prophylaxis of Kidney Diseases of Non-inflammatory etiology in mammals is described herein. The method comprises administering Hydroxychloroquine, its enantiomer or a pharmaceutically acceptable salt thereof or its combinations with at least one drug selected from the group of angiotensin receptor blockers and angiotensin converting enzyme inhibitors. More particularly, a method is provided for treatment and/or prophylaxis of Diabetic Kidney Disease in mammals, which comprises administering a therapeutically effective amount of Hydroxychloroquine, its enantiomer or a pharmaceutically acceptable salt thereof or its combinations with an angiotensin receptor blockers or an ACE inhibitors. Pharmaceutical compositions are provided for the above treatment.

Abstract: The present invention discloses a pharmaceutical combination comprising Hydroxychloroquine and a DPP-IV inhibitor or their pharmaceutically acceptable salts, solvates or prodrugs thereof, for preventing, slowing the progression of, delaying, improving, restoring, or treating a condition or a disease resulting from metabolic disorders.

Abstract: Disclosed herein is a pharmaceutical composition comprising Hydroxychloroquine or its pharmaceutically acceptable salt and at least one antidiabetic compound, useful in the treatment of diabetes mellitus.

Abstract: Disclosed herein is a novel synergistic pharmaceutical composition comprising hydroxychloroquine with insulin sensitizing agents and lipid lowering agents such as statins along with pharmaceutical excipients/carriers useful in treating Non-Alcoholic Fatty Liver Disease.

Abstract: Disclosed herein is a pharmaceutical composition comprising Hydroxychloroquine or its pharmaceutically acceptable salt and at least one antidiabetic compound, useful in the treatment of diabetes mellitus.